Inflammatory disorders

Two new studies evaluate agents for treating ulcerative colitis

In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures. ...

Diseases, Conditions, Syndromes

Side effects of biologics for rheumatic Dz may up anxiety

(HealthDay)—Potential side effects of biological agents may increase anxiety in patients with rheumatic disease, according to research published in the June issue of the International Journal of Rheumatic Diseases.

Parkinson's & Movement disorders

Toward a better understanding of Parkinson's disease

A new study, published today in Nature Structural and Molecular Biology, moves researchers closer to understanding one of the crucial proteins involved in Parkinson's disease.

Diseases, Conditions, Syndromes

Psoriasis may up risk of melanoma, hematologic cancer

(HealthDay)—Patients with psoriasis may have a higher risk of melanoma and hematologic cancers than the general population, according to a study published in the April issue of the Journal of the American Academy of Dermatology.

page 1 from 6